# name
Eculizumab as a promising treatment in thymoma-associated myasthenia gravis

# metadata.dc.description.abstract[].value
Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis. Eculizumab, a monoclonal antibody that inhibits the activation of terminal complement, has recently been approved for the treatment of refractory generalized myasthenia gravis. This is an early case report of thymoma-associated refractory myasthenia gravis successfully treated with eculizumab in a real-world setting.

# metadata.dc.relation.ispartof[].value
Therapeutic Advances in Neurological Disorders, 2020, vol. 13

# metadata.dc.rights[].value
cc by-nc (c) Vélez Santamaria et al., 2020

# metadata.dc.source[].value
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

# metadata.dc.title[].value
Eculizumab as a promising treatment in thymoma-associated myasthenia gravis